• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

FDA Drug Shortages

  • Print
  • Share
  • E-mail
-

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

 Trimipramine Maleate (SURMONTIL) Capsules

 Status: Currently in Shortage

 » Date first reported: 08/18/2014
 » Therapeutic Categories: Psychiatry

Mikah Pharma, LLC c/o Epic Pharma, LLC (New 08/19/2014)

Company Contact Information:
908-437-8232

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg 30s (NDC 45963-293-30) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient
25 mg 90s (NDC 45963-293-08) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient
25 mg 270s (NDC 45963-293-27) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient
50 mg 30s (NDC 45963-294-30) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient
50 mg 90s (NDC 45963-294-08) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient
50 mg 270s (NDC 45963-294-27) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient
100 mg 30s (NDC 45963-295-30) Product currently unavailable API manufacturer discontinued the material Shortage of active ingredient

Teva Pharmaceuticals (Revised 10/06/2014)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
SURMONTIL(R) CAPSULES 50MG 100 (NDC 51285-0539-02) Replenishment of all presentations expected by mid-September 2014. Other
SURMONTIL(R) CAPSULES 25MG 100 (NDC 51285-0538-02) Product is currently available. Other
SURMONTIL(R) CAPSULES 100MG 100 (NDC 51285-0554-02 ) Replenishment of all presentations expected by mid-September 2014. Other
-
-